220 related articles for article (PubMed ID: 35771259)
21. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Le X; Sakai H; Felip E; Veillon R; Garassino MC; Raskin J; Cortot AB; Viteri S; Mazieres J; Smit EF; Thomas M; Iams WT; Cho BC; Kim HR; Yang JC; Chen YM; Patel JD; Bestvina CM; Park K; Griesinger F; Johnson M; Gottfried M; Britschgi C; Heymach J; Sikoglu E; Berghoff K; Schumacher KM; Bruns R; Otto G; Paik PK
Clin Cancer Res; 2022 Mar; 28(6):1117-1126. PubMed ID: 34789481
[TBL] [Abstract][Full Text] [Related]
22. Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Ahn L; Alexander T; Vlassak S; Berghoff K; Lemmens L
Clin J Oncol Nurs; 2022 Sep; 26(5):543-551. PubMed ID: 36108212
[TBL] [Abstract][Full Text] [Related]
23. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Tanaka H; Taima K; Makiguchi T; Nakagawa J; Niioka T; Tasaka S
Cancer Commun (Lond); 2021 Jan; 41(1):83-87. PubMed ID: 33387444
[TBL] [Abstract][Full Text] [Related]
24. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Ryoo BY; Cheng AL; Ren Z; Kim TY; Pan H; Rau KM; Choi HJ; Park JW; Kim JH; Yen CJ; Lim HY; Zhou D; Straub J; Scheele J; Berghoff K; Qin S
Br J Cancer; 2021 Jul; 125(2):200-208. PubMed ID: 33972742
[TBL] [Abstract][Full Text] [Related]
25. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
26. Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
Hu X; Cui X; Wang Z; Liu Y; Luo Y; Zhong W; Zhao H; Yao M; Jiang D; Wang M; Chen M; Zheng X; Ding L; Wang Y; Yuan X; Wu P; Hu B; Han X; Shi Y
BMC Cancer; 2023 Apr; 23(1):331. PubMed ID: 37041472
[TBL] [Abstract][Full Text] [Related]
27. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
Roth KG; Mambetsariev I; Salgia R
Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33335011
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Shitara K; Yamazaki K; Tsushima T; Naito T; Matsubara N; Watanabe M; Sarholz B; Johne A; Doi T
Jpn J Clin Oncol; 2020 Aug; 50(8):859-866. PubMed ID: 32328660
[TBL] [Abstract][Full Text] [Related]
29. Brief Report: Tepotinib as a Treatment Option in
Miyashita Y; Hirotsu Y; Nagakubo Y; Kobayashi H; Kawaguchi M; Hata K; Saito R; Kakizaki Y; Tsutsui T; Oyama T; Omata M
JTO Clin Res Rep; 2024 Jun; 5(6):100679. PubMed ID: 38841537
[TBL] [Abstract][Full Text] [Related]
30. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
31. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
32. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
Xia Y; Jin R; Li M; Lan F; Zhu H; Yu Y; Miao D; Wang Q; Zhou Y; Selvaggi G; Ying S; Zhang J; Shen H; Le X; Li W
Cancer Lett; 2023 May; 561():216140. PubMed ID: 36948240
[TBL] [Abstract][Full Text] [Related]
33. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Decaens T; Barone C; Assenat E; Wermke M; Fasolo A; Merle P; Blanc JF; Grando V; Iacobellis A; Villa E; Trojan J; Straub J; Bruns R; Berghoff K; Scheele J; Raymond E; Faivre S
Br J Cancer; 2021 Jul; 125(2):190-199. PubMed ID: 33824476
[TBL] [Abstract][Full Text] [Related]
34. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
Pruis MA; Krebs MG; Plummer R; De Vos F; Angevin E; Prenen H; Forster MD; Clack G; Van der Aa A; Tjwa M; Jansen E; Perera T; Lolkema MP
Oncologist; 2023 Dec; 28(12):e1248-e1258. PubMed ID: 37260332
[TBL] [Abstract][Full Text] [Related]
35. Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.
Kunimasa K; Kawamura T; Tamiya M; Inoue T; Kuhara H; Nishino K; Kumagai T
Thorac Cancer; 2021 Dec; 12(24):3426-3428. PubMed ID: 34695875
[TBL] [Abstract][Full Text] [Related]
36. Going After
Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
[TBL] [Abstract][Full Text] [Related]
37. Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation.
Vanderick A; Colinet B
Acta Clin Belg; 2024 Apr; 79(2):148-151. PubMed ID: 38494868
[TBL] [Abstract][Full Text] [Related]
38. The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J; Friese-Hamim M; Clark A; Schadt O; Walter-Bausch G; Stroh C; Johne A; Karachaliou N; Blaukat A
Mol Cancer Ther; 2023 Jul; 22(7):833-843. PubMed ID: 36999986
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the
Sohn SH; Sul HJ; Kim BJ; Zang DY
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339049
[TBL] [Abstract][Full Text] [Related]
40. Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding.
Grädler U; Schwarz D; Wegener A; Eichhorn T; Bandeiras TM; Freitas MC; Lammens A; Ganichkin O; Augustin M; Minguzzi S; Becker F; Bomke J
J Biol Chem; 2023 Nov; 299(11):105328. PubMed ID: 37806493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
